Regulation of gap junction assembly

Across TCGA cell cohorts, RNA activity of the Regulation of gap junction assembly pathway is significantly associated with the drug response of multiple features, with the BREAST cohort showing a particularly strong set of associations.

The most reproducible pathway-associated features across cancer lineages are Veliparib, CCT007093, and EHT-1864, each associated with the pathway in up to 1 cancer types. Since the analysis shows associations rather than directional relationships, both pathway-to-partner and partner-to-pathway views are reported.

Each partner is linked to its corresponding Q-omics profile. The box plot shows the strongest association, Veliparib grouped by Regulation of gap junction assembly-low versus -high activity in BREAST.

Pathway-associated features by consensus

Ranked by combined sampling and lineage consensus. X-score (pathway→partner) and Y-score (partner→pathway) are standardized regression coefficients; both directions are reported because the association is undirected. The reported p-values are derived from the association test.

Lineage	Partner feature	X-score	Y-score	p(X)	p(Y)	Sampling consensus	Lineage consensus
BREAST	Veliparib →	-0.345	-1.717	.029	.011	1	1
BREAST	CCT007093 →	-0.765	-1.717	.007	.011	1	1
BREAST	EHT-1864 →	-0.655	-1.717	.031	.011	1	1
BREAST	Niraparib →	-0.495	-1.717	.040	.011	1	1
BREAST	Dinaciclib →	-1.844	-1.717	.043	.011	1	1
BREAST	FY069 →	-1.185	-1.717	.012	.011	1	1

Each partner links to its Q-omics profile. Showing the 6 strongest associations by consensus.

Veliparib by Regulation of gap junction assembly activity — BREAST

Explore this box plot interactively →